Dr. Frye is the Director of Autism Research at Arkansas Children’s Hospital/University of Arkansas Medical Sciences in Little Rock, AR. He is a recognized expert in the diagnosis and treatment of ASD and other developmental disorders. His broad background includes specific training in neurodevelopmental disorders, physiology, psychology and biostatistics. He is fellowship-trained in Behavioral Neurology and Psychology and has clinical expertise in the assessment, diagnosis and treatment of children with ASD.

While at the University of Texas, he developed a medically-based autism clinic, specifically designed to diagnose and treat neurological and metabolic abnormalities associated with ASD in order to improve quality of life and promote recovery. Over the past two years he has completed three clinical studies related to ASD, including an open-label trial examining the metabolic and behavioral effects of tetrahydrobiopterin, a clinical study of the metabolic and genetic characteristics of children with ASD and mitochondrial disease, and a clinical study on the prevalence of the folate receptor alpha autoantibody in children with ASD as well as the response to leucovorin treatment in ASD children with the folate receptor alpha autoantibody.

As Director of Autism Research at the Arkansas Children’s Hospital, he strives to develop an integrated autism program that includes a multi-specialty autism clinic, a translational research program focusing on biomarkers and clinical-trials and a basic science program focusing on mitochondrial and redox metabolic metabolism.